Skip to content

A randomized, double-blind, controlled clinical trial of Suhe Granules for chronic insomnia patients with Disharmony of Qi and Blood and Deficiency of Heart and Kidney

A randomized, double-blind, controlled clinical trial of Suhe Granules for chronic insomnia patients with Disharmony of Qi and Blood and Deficiency of Heart and Kidney

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200006603
Enrollment
Unknown
Registered
2022-09-15
Start date
2022-10-15
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

insomnia

Interventions

The cotrol group:placebo
The test group:Shuhe Granules

Sponsors

Guangdong Provincial Hospitai of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: (1) 18 years old or older; (2) Meet the diagnostic criteria for chronic insomnia of International Classification of Diseases-11(ICD-11); (3) Meet the diagnostic criteria of Shuhe Granules: Cold or wind intolerance, daytime mental fatigue, palpitations or dizziness, pale lower eyelids or red at the edge of lower eyelids, low menstrual flow and cold hands; (4) Signed the informed consent form;

Exclusion criteria

Exclusion criteria: (1) Meet any criteria of the eliminating symptoms eliminating symptoms: a. The lower eyelid is completely red b. Hand baking heat c. The stool is dry and(or) hard d. The moss is thick or dry and rough e. The pulse-to-breath ratio is greater than 5 (2) People who are preparing to become pregnant or pregnant or breastfeeding, or who need to accompany their children to sleep; (3) According to the medical history and consultation, the doctor confirms that secondary insomnia caused by other diseases. For example: local pain, restless legs syndrome, sleep apnea syndrome, acute and chronic heart failure, chronic obstructive pulmonary disease, acute and chronic bronchitis, etc.; (4) Diagnosis of severe depression patients according to the Patient Health Questionnaire-9 (PHQ-9)(total score =15); (5) Diagnosis of patients with severe anxiety according to the Generalised anxiety disorder-7(GAD-7)(total score =15); (6) Those who have participated in clinical trials of other drugs in the past 30 days; (7) Patients with other mental illnesses

Design outcomes

Primary

MeasureTime frame
The total socres of Insomnia Severity Index(ISI);

Secondary

MeasureTime frame
The total score of Fatigue Scale-14(FS-14);The total scores and the various scores of the Pittsburgh sleep quality index;The total score of the Patient Health Questionnaire-9 (PHQ-9);The total score of the Sleep Diary;The total score of the Generalised anxiety disorder-7(GAD-7);

Countries

China

Contacts

Public ContactZhimin Yang
yangyovip@126.com13822296363

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026